Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575831 | 0.90 | PPARA (0.43) | PPARAPPARDPPARGSTAT3LMNA | |
| SCHEMBL4574848 | 0.90 | LMNA (0.43) | PPARAPPARDPPARGLMNATSHR | |
| SCHEMBL4575447 | 0.89 | FFAR1 (0.43) | PPARAPPARDPPARGSTAT3LMNA | |
| SCHEMBL4598247 | 0.88 | PPARA (0.43) | PPARAPPARDPPARGS1PR1LMNA | |
| SCHEMBL4575966 | 0.88 | FABP1 (0.40) | PPARAPPARDPPARGS1PR1LMNA | |
| SCHEMBL4575126 | 0.88 | TUBB4A (0.41) | PPARAPPARDPPARGS1PR1LMNA | |
| SCHEMBL4576160 | 0.87 | PPARA (0.44) | PPARAPPARDPPARGLMNATSHR | |
| SCHEMBL4575348 | 0.87 | NPC1 (0.41) | PPARAPPARDPPARGNPY2RLMNA | |
| SCHEMBL4575686 | 0.87 | PPARA (0.42) | PPARAPPARDPPARGLMNATSHR | |
| SCHEMBL4576216 | 0.87 | MEN1 (0.41) | PPARAPPARDPPARGS1PR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PPARA 2/4885PPARD 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.